Detalhe da pesquisa
1.
Sorafenib for Advanced and Refractory Desmoid Tumors.
N Engl J Med
; 379(25): 2417-2428, 2018 12 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30575484
2.
Correlates of response and outcomes with talimogene laherperpvec.
J Surg Oncol
; 120(3): 558-564, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31264725
3.
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 19(7): 916-929, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29908991
4.
Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases.
J Cutan Pathol
; 45(1): 48-53, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28940544
5.
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.
N Engl J Med
; 364(22): 2119-27, 2011 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-21631324
6.
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.
J Clin Oncol
; 41(2): 186-197, 2023 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36166727
7.
Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma.
Cancer Discov
; 12(3): 644-653, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34764195
8.
Control and Toxicity in Melanoma Versus Other Brain Metastases in Response to Combined Radiosurgery and PD-(L)1 Immune Checkpoint Inhibition.
Adv Radiat Oncol
; 6(1): 100561, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33665483
9.
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53.
Clin Cancer Res
; 27(19): 5236-5247, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34301750
10.
Evolution of Immune Checkpoint Blockade-Induced Myocarditis Over 2 Years.
JACC Case Rep
; 2(2): 203-209, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34317205
11.
Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover.
Cancers (Basel)
; 12(7)2020 Jun 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-32610581
12.
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial.
Nat Med
; 26(10): 1564-1568, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33020646
13.
Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer.
Clin Cancer Res
; 14(15): 4843-9, 2008 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18676757
14.
Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1).
Melanoma Manag
; 6(2): MMT19, 2019 Jul 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31406563
15.
E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma.
Clin Cancer Res
; 25(2): 524-532, 2019 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30420448
16.
Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies.
Pigment Cell Melanoma Res
; 32(4): 553-563, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30767428
17.
Clinical characterization of colitis arising from anti-PD-1 based therapy.
Oncoimmunology
; 8(1): e1524695, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30546965
18.
Acute inflammatory thyromegaly following checkpoint inhibition: A new imaging entity?
Radiol Case Rep
; 13(1): 89-91, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29552247
19.
Talimogene laherparepvec: First in class oncolytic virotherapy.
Hum Vaccin Immunother
; 14(4): 839-846, 2018 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29420123
20.
Malignant Ewing-Like Neoplasm With an EWSR1-KLF15 Fusion: At the Crossroads of a Myoepithelial Carcinoma and a Ewing-Like Sarcoma. A Case Report With Treatment Options.
Int J Surg Pathol
; 26(5): 440-447, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-29390927